Project Details
Description
A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7
Status | Finished |
---|---|
Effective start/end date | 6/1/17 → 11/1/17 |
Funding
- ULTRAGENYX PHARMACEUTICAL INC.